Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
Combined immunotherapy employing Wilms' tumor 1 peptide-pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogasawara Masahiro, Miyashita Mamiko, Yamagishi Yuka, Ota Shuichi
Аннотация
INTRODUCTION: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. This study evaluated the safety, immune responses, and clinical outcomes of Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination combined with hormone or chemotherapeutic agents in mCRPC patients.
METHODS: WT1 peptide-loaded mature DCs were administered intradermally and the adjuvant OK-432 every 2-4 weeks. WT1-specific immune responses were assayed using ELISpot, HLA-tetramer, and CD107a assays.
RESULTS: Vaccination was well tolerated with no severe adverse events. WT1-specific immune responses were significantly enhanced in patients with stable disease (SD), along with reduced regulatory T cells. A PSA reduction of >50% was achieved in 35.7% of patients. Median overall survival (mOS) was 28.5 months, exceeding the Halabi nomogram's estimate (19.0 months). Patients with WT1-specific immune responses exhibited significantly longer mOS, suggesting a link between WT1-specific immunity and favorable outcomes.
CONCLUSION: This immunotherapy approach shows promise for improving survival in mCRPC patients.
METHODS: WT1 peptide-loaded mature DCs were administered intradermally and the adjuvant OK-432 every 2-4 weeks. WT1-specific immune responses were assayed using ELISpot, HLA-tetramer, and CD107a assays.
RESULTS: Vaccination was well tolerated with no severe adverse events. WT1-specific immune responses were significantly enhanced in patients with stable disease (SD), along with reduced regulatory T cells. A PSA reduction of >50% was achieved in 35.7% of patients. Median overall survival (mOS) was 28.5 months, exceeding the Halabi nomogram's estimate (19.0 months). Patients with WT1-specific immune responses exhibited significantly longer mOS, suggesting a link between WT1-specific immunity and favorable outcomes.
CONCLUSION: This immunotherapy approach shows promise for improving survival in mCRPC patients.